NCT01420146View on ClinicalTrials.gov

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Breast NeoplasmsSecondaryHER2 Positive Carcinoma of Breast
Interventions
DRUG

Zr89-trastuzumab

trastuzumab labelled with zirconium 89 for PET/CT

Trial Locations (1)

1000

Jules Bordet Institut, Brussels

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER